Cinnagen

CinnaGen is an Iran based biotechnology company that was founded in 1994 by four scientists. As of 2016, it manufactured biosimilar drugs, laboratory diagnostic reagents for in vitro use, and recombinant proteins, and exported to other countries in the Middle East and to countries in the Commonwealth of Independent States.[1]:70

One of CinnaGen's products is Cinnovex, a biosimilar of interferon-beta used for treatment of multiple sclerosis; the recombinant DNA used to make the product was created by scientists at Fraunhofer Institute in Germany which also conducted the initial testing; Fraunhofer licensed it to CinnaGen which completed development and obtained approval from Iranian Food and Drug Administration in 2007.[2][3]

See also

References
  1. Science, Technology and Innovation Policy Review: Iran (PDF). United Nations Conference on Trade and Development. 2016.
  2. "Aus Deutschland für Kranke in Iran (From Germany for the sick in Iran)". Wiener Zeitung (in German). 2007-03-20. |access-date= requires |url= (help)
  3. "Erstes biogenerisches therapeutisches Protein aus Fraunhofer-Labor für den Markt zugelassen". BioRegio STERN (in German). 2007-01-19. Archived from the original on 2017-10-20. Retrieved 2017-10-20.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.